FABP3 Human
Human heart tissue.
Fatty acid-binding protein heart, H-FABP, Heart-type fatty acid-binding protein, Muscle fatty acid-binding protein, M-FABP, Mammary-derived growth inhibitor, MDGI, FABP3, FABP11, O-FABP.
Sterile Filtered White lyophilized (freeze-dried) powder.
Greater than 95.0% as determined by SDS-PAGE.
Description
FABP3 Human produced in Human cardiac muscle tissue having a molecular mass of
15kDa and is purified by proprietary chromatographic technique.
Product Specs
Fatty acid-binding protein heart, H-FABP, Heart-type fatty acid-binding protein, Muscle fatty acid-binding protein, M-FABP, Mammary-derived growth inhibitor, MDGI, FABP3, FABP11, O-FABP.
Human heart tissue.
Product Science Overview
Fatty Acid Binding Protein-3 (FABP3), also known as Heart-type Fatty Acid Binding Protein (H-FABP), is a member of the fatty acid-binding protein family. These proteins are crucial for the intracellular transport of fatty acids and other lipophilic substances. FABP3 is predominantly expressed in cardiac and skeletal muscles, where it plays a significant role in lipid metabolism and energy production.
FABP3 is a small, cytoplasmic protein that binds long-chain fatty acids and other hydrophobic ligands. The primary function of FABP3 is to facilitate the transport of fatty acids from the cell membrane to various intracellular sites, including the mitochondria, where they undergo β-oxidation to produce energy. Additionally, FABP3 is involved in the regulation of gene expression and cellular signaling pathways related to lipid metabolism.
FABP3 is integral to several metabolic processes, particularly in tissues with high energy demands such as the heart and skeletal muscles. It ensures the efficient utilization of fatty acids as an energy source, which is vital for maintaining cellular function and overall energy homeostasis. Dysregulation of FABP3 expression or function can lead to metabolic disorders, including insulin resistance, obesity, and cardiovascular diseases .
FABP3 has garnered significant attention as a potential biomarker for various diseases. Elevated levels of FABP3 in the bloodstream are indicative of myocardial injury, making it a valuable marker for the early diagnosis of acute myocardial infarction. Furthermore, research has shown that FABP3 is associated with peripheral arterial disease (PAD) and other cardiovascular conditions .
Recent studies have highlighted the role of epigenetic modifications in regulating FABP3 expression. For instance, CpG methylation in the promoter region of the FABP3 gene has been linked to metabolic syndrome phenotypes, including dyslipidemia, insulin resistance, and hypertension. These findings suggest that epigenetic mechanisms may influence FABP3 expression and its associated metabolic functions .
